GravesGraves病治疗前后血清甲状腺相关抗体的改变
Changes of serum thyroid-related antibodies before and after the treatment in patients with Graves disease
摘要
Graves病（Graves＇disease,GD）是临床上最常见的甲状腺自身免疫性疾病,以血中升高的促甲状腺素受体抗体（thyroid-stimulating hormone receptor antibody,TRAb）为主要的免疫学标志。但临床中不乏GD患者甲状腺球蛋白抗体（thyroglobulin antibody,TGAb）及甲状腺过氧化物酶抗体（thyroid peroxidase antibody,TPOAb）阳性的情况。本研究主要观察初发GD患者,治疗12个月前后3个甲状腺相关抗体的情况,现报告如下。
出处
《武警后勤学院学报（医学版）》
CAS
2016年第5期393-394,共2页
Journal of Logistics University of PAP（Medical Sciences）
参考文献8
-
1Pearce EN, Hennessey JV, McDermott MT. New American thyroid association and american association of clinical en- docrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research[J]. Tyroid, 2011, 21(6):573-576.
-
2Waiiaschofski H, Miehie K, Mayer A, et al. Prediction ofremission or relapse for Graves' hyperthyroidism by the combined determination ofstimuiating, biockingand binding TSH- receptor antibodiesafterthewithdrawaiofantithyroid drugtreatment[J]. HormMetab Res, 2002, 34(7):383-388.
-
3Stefanie M, Karner I. Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyper- thyroidism after successful non-ablative treatment of Graves' disease in Croatian patients[J]. J Endocrinol Invest, 2014, 37 (1):71-77.
-
4Hanna M, Marcin M, Monika OM, et al. The role of the im- mune system and cytokines involved in the pathogenesis of autoimmune thyroid disease(AITD)[J]. Endocrin Polska, 2014, 65(2):150-155.
-
5Eskes SA, Endert E, Flier D, et al. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies[J]. Clin Endocrinol, 2014, 80(3):444-451.
-
6Weetman AP. Autoimmune thyroid disease:propagation and progression[J]. Eur J Endocrinol, 2003, 148(1):1-9.
-
7McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens:changing concepts in thyroid autoimmunity[J]. Endocr Rev, 2014, 35(1):59-105.
-
8Predro Ana Beatriz B, Romaldini Joho H, et al. Changes of Serum cytokines in hyperthyroid graves' disease patients at diagnosis and during methimazole treatment[J]. Neuroimmu- nomodulation, 2011,189(1):45-51.
-
1卢泽芬,于佳,任丽萍,郝杰,何庆.甲状腺自身抗体对初发GD患者甲状腺功能的影响的研究[J].解放军预防医学杂志,2016,34(S2):9-9. 被引量：5
-
2朱宏伟,李华,李志辉.甲亢性肝损害与IL-23/Th17轴细胞因子的相关性分析[J].中国处方药,2017,15(1):135-136. 被引量：3
-
3张雪莲.甲状腺相关抗体与甲状腺疾病[J].中国全科医学（医生读者版）,2013,16(2):35-37.
-
4窦家庆,荚静芳.Graves病患者131碘治疗后甲状腺相关抗体的变化及意义[J].安徽医药,2015,19(12):2377-2379. 被引量：6
-
5高莹,刘明明,修瑞娟.桥本甲状腺炎的免疫学发病机制进展[J].内科理论与实践,2013,8(6):392-396. 被引量：16
-
6蒿自睿.聚乙二醇干扰素α-2a治疗慢性丙型肝炎对甲状腺功能及甲状腺相关抗体影响临床研究[J].现代诊断与治疗,2016,27(9):1666-1667. 被引量：1
-
7张雪扬.2型糖尿病患者合并甲状腺疾病的临床调查[J].医学与哲学（B）,2015,36(5):39-41. 被引量：7
-
8王环,陈洁.甲瘤胶囊治疗桥本甲状腺炎合并结节30例[J].安徽中医药大学学报,2016,35(1):27-29. 被引量：4
-
9黄晶,刘安宁,张高生.桥本甲状腺炎患者外周血IL-8的表达及意义研究[J].中国卫生检验杂志,2015,25(2):217-219. 被引量：4
-
10赵义刚,勾正兴,聂忠荣,宋波.^(131)I治疗220例Graves甲亢患者的疗效分析[J].现代医药卫生,2008,24(15):2312-2313. 被引量：2
